Nventa is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by the human papillomavirus (HPV). The corporation is publicly traded on the Toronto Stock Exchange. The company was previously known as Stressgen Pharmaceuticala and changed name in June 2006.
R&D
To view this information, you must subscribe to PL Intelligence.
Partnerships
To view this information, you must subscribe to PL Intelligence.
Deals
To view this information, you must subscribe to PL Intelligence.
Senior management
To view this information, you must subscribe to PL Intelligence.
Board of directors
To view this information, you must subscribe to PL Intelligence.
Head office
Nventa Biopharmaceuticals
9381 Judicial Drive, Suite 180
San Diego
California
92121 California
All rights reserved. Terms and Conditions | Contact us
